Alopecia Areata Video Perspectives
Emma Guttman-Yassky, MD, PhD
Disclosures
Guttman-Yassky reports financial relationships with AbbVie, Almirall, Amgen, AnaptysBio, Arena, Asana Biosciences, Aslan Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, Cara Therapeutics, Celgene, Connect Pharma, Eli Lilly, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Innovaderm, Janssen Biotech, Kyowa Kirin, LEO Pharma, Novartis, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Sanofi, SATO Pharmaceutical, Siolta Therapeutics, Target Pharma Solutions, UCB and Ventyx Biosciences.
October 11, 2023
1 min watch
Save
VIDEO: Patients need better education about alopecia areata
Transcript
Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
They need to be aware of the fact that, they need to address, first of all to the patient, what is alopecia areata? What are the triggers of alopecia areata? Patients will always ask, "Do I need to take this treatment for life? And the answer may be maybe not for life, but for quite some time until we have something that maybe switches the trigger. They need to understand what are the immune pathways involved? What are the new treatments coming into alopecia areata? All of this needs to be addressed.
